Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Peter J, Schlegel"'
Autor:
Nafisa Burhani, Hani M. Babiker, Emad Elquza, Andrea J. Bullock, Ely Benaim, Allyson J. Ocean, Lee G. Hicks, Peter J. Schlegel, Christine B. Peterson, Daruka Mahadevan, Mitesh J. Borad, Callie Heaton
Publikováno v:
Investigational New Drugs. 40:81-90
Background RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by cancer cells over-expressing uridine cytidine kinase 2 (UCK2). Single agent RX-3117 demonstrated efficacy in a phase I trial in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8841b5475e5beb9575ab758350b71ace
https://doi.org/10.1007/s10637-021-01164-9
https://doi.org/10.1007/s10637-021-01164-9
Autor:
Hani, Babiker, Peter J, Schlegel, Lee G, Hicks, Andrea J, Bullock, Nafisa, Burhani, Daruka, Mahadevan, Emad, Elquza, Mitesh J, Borad, Ely, Benaim, Christine, Peterson, Callie, Heaton, Allyson J, Ocean
Publikováno v:
Investigational new drugs. 40(1)
Background RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by cancer cells over-expressing uridine cytidine kinase 2 (UCK2). Single agent RX-3117 demonstrated efficacy in a phase I trial in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::651202fed5992602007b5c919335cd35
https://pubmed.ncbi.nlm.nih.gov/34417914
https://pubmed.ncbi.nlm.nih.gov/34417914
Autor:
Lee G. Hicks, Peter J. Schlegel, Hani M. Babiker, Andrea J. Bullock, Nafisa Burhani, Callie Heaton, Christine B. Peterson, Ely Benaim, Allyson J. Ocean
Publikováno v:
Journal of Clinical Oncology. 37:420-420
420 Background: RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by cancer-enriched uridine cytidine kinase 2. Single agent RX-3117 has demonstrated efficacy in a phase III single agent clinical stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e70a6ae1a28574f86e31de1f9e86b45
https://doi.org/10.1200/jco.2019.37.4_suppl.420
https://doi.org/10.1200/jco.2019.37.4_suppl.420
Autor:
Roger M. Lyons, Yunfei Wang, Philip Y. Dien, Nicholas J. Di Bella, Robert N. Raju, Julie Boston, Kathryn S. Kolibaba, Svetislava J. Vukelja, David Barrera, Raymond Taetle, Peter J. Schlegel, Thomas E. Boyd, Lina Asmar, Kristi A. Boehm, Ernest W. Cochran
Publikováno v:
Blood. 115:475-480
This study evaluated the efficacy and safety of single-agent bortezomib in indolent B-cell lymphoma that had relapsed from or was refractory to rituximab. Sixty patients enrolled: 59 were treated with bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d55ec35c8ddf369b27ca9c691a5c244
https://doi.org/10.1182/blood-2009-08-233155
https://doi.org/10.1182/blood-2009-08-233155
Publikováno v:
The American Journal of Medicine. 107:643-645
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49a25d0d582eea1c2af657c646a1c7a9
https://doi.org/10.1016/s0002-9343(99)00250-8
https://doi.org/10.1016/s0002-9343(99)00250-8
Publikováno v:
Journal of Immunotherapy. 23:507-508
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13c592b3f3ce52943089fee90fbf1f21
https://doi.org/10.1097/00002371-200007000-00016
https://doi.org/10.1097/00002371-200007000-00016
Autor:
Lina Asmar, Yunfei Wang, Kristi A Boehm, Julie Boston, Svetislava J Vukelja, Peter J Schlegel, Roger M. Lyons, David Hakimian, Philip Dien, Ernest Cochran, David N Barrera, Robert N Raju, Thomas E Boyd, Kathryn S. Kolibaba, Raymond Taetle, Nicholas Di Bella
Publikováno v:
Blood. 112:1572-1572
This study was designed to evaluate the efficacy and safety of bortezomib as monotherapy in patients (pts) with indolent B-cell lymphoma who have relapsed following, or who are refractory to, rituximab therapy. A total of 60 patients enrolled and 59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0aea8e8bfbf30f5fb46c8fd50dcf705
https://doi.org/10.1182/blood.v112.11.1572.1572
https://doi.org/10.1182/blood.v112.11.1572.1572